.svg)
Potential Challenges in Anti-angiogenic Nanotherapies and Conclusion
| dc.contributor.author | Mukherjee S.; Madamsetty V.S. | |
| dc.date.accessioned | 2025-05-23T11:23:41Z | |
| dc.description.abstract | Since last few decades, several nanoparticles-based medicines were tested and clinically used for various biomedical applications including cancer (Mukherjee et al. in Theranostics 9:7730–7748, 2019, [1]; Mukherjee et al. Adv Funct Mater 30(35) 2003054, 2019, [2]). Unfortunately, many nanoparticles-based materials demonstrate short-term or long-term toxicity in human or environmental species. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG. | |
| dc.identifier.doi | https://doi.org/10.1007/978-3-031-11284-3_6 | |
| dc.identifier.uri | http://172.23.0.11:4000/handle/123456789/9267 | |
| dc.relation.ispartofseries | Synthesis Lectures on Biomedical Engineering | |
| dc.title | Potential Challenges in Anti-angiogenic Nanotherapies and Conclusion |